- Maine Caucuses a Chance to Right the Romney Ship
- Greek Debt Saga Back on Center Stage for Markets
- Greece Now Struggles to Overcome Mistrust
- Obama Budget Bets Other Concerns Will Trump the Deficit
- China President-in-Waiting to Sample Slices of America
- MF Global Trustee Sees Shortfall of $1.6 Billion
- Iran to Announce 'Very Important' Nuclear Progress
- Traveling Light in a Time of Digital Thievery
- UK Police Arrest Five at Murdoch's Sun Newspaper
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
MOST SHARED
- UK's Cameron Calls for Truce on Bonuses
- Greek Debt Saga Back on Center Stage for Markets
- For China's Xi, Near-Summit Treatment and 'Iowa Nice'
- Greece Warns Bailout Rebels of Unknown, Dangerous Path
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- How Rescuing Greece Could Destroy the World
- Greek Police Union Wants to Arrest EU, IMF Officials
- Warren Buffett's 5-Minute Plan to Fix the Deficit
- Dividend Payout Could Hit Record Amount This Year
MOST POPULAR
HOT ON FACEBOOK
Invitrogen to Buy Applied Biosystems for $6.7 Billion
Text Size 
Invitrogen plans to buy Applied Biosystems in a deal valued at $6.7 billion to form a massive provider of research tools for the life sciences industry, the companies said on Thursday.
The purchase price of $38 per share in cash and stock represents a premium of 17 percent over Applied Biosystems' closing price on Wednesday and 12 percent over its average closing price over the past 30 days. The split is expected to be 45 percent cash and 55 percent Invitrogen stock.
The combined company will generate about $3.5 billion in combined sales, offering a wide variety of products in areas such as genetic analysis, proteomics, cell biology and cell systems.
Applied Biosystems' equipment includes mass spectrometers, which can measure the molecular weight of proteins and thereby identify them.
Invitrogen [IVGN
Loading...
()
] shares fell 10 percent after the deal announcement, while Applied Biosystems [ABI
Loading...
()
] rose 8 percent.
"In the most general terms, it makes sense in terms of their expertise in molecular biology, efficiencies in combined sales forces, overlap on product line and intellectual property interests," said Deutsche Bank analyst Ross Muken. Such a combination was a source of speculation at a conference in Denver last week, he added.
Upon closing, Invitrogen shareholders would own the majority of the merged company, which would be named Applied Biosystems.
Applied Biosystems is one of two tracking stocks of Applera, which announced the deal with Invitrogen. Celera Group [CRA
Loading...
()
] is the other.
The companies expect the merger to close in the fall and to be neutral to or slightly help earnings per share in the first year and significantly positive in the second year.
Invitrogen shares fell $4.35 to $39 in early electronic trading from a Wednesday close of $43.35 on Nasdaq.
Applied Biosystems shares rose to $35 from Wednesday's New York Stock Exchange close of $32.44.
- Marketing clichés aside, sometimes diamonds are for investing.
- The ‘Fast Money’ traders weigh in on fashion related stocks from apparel to footwear.
- This list of the 10 most active cities for speed traps was compiled by Trapster.com. See if your town is there.
- This Valentine’s Day should prove a love fest for restaurants, as many couples will be dining out.
- Here’s a look at Westminster Kennel Club’s most successful breeds—and how much they cost.
- What kind of homes do celebrity couples share? Here’s our updated list. Take a look.
Data is a real-time snapshot *Data is delayed at least 15 minutes
